The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwHRMM 2026 | Considerations & challenges for bringing long-read sequencing into routine myeloma diagnostics
Sarah Gooding, MD, PhD, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, discusses the challenges of transitioning long-read sequencing of the myeloma genome from a research tool to a routine diagnostic workflow. Dr Gooding emphasizes the importance of ensuring equitable access to testing, particularly in resource-limited settings, and notes that the development of a flexible and relatively affordable assay could provide a huge amount of information for future use. This interview took place at the 3rd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2026), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
